Global Pediatric Orphan Drugs Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global Pediatric Orphan Drugs Market Research Report 2024
Pediatric orphan drugs are medications that are specifically developed and approved for the treatment of rare diseases or conditions in children. These drugs are designed to address medical needs in pediatric populations who have limited treatment options due to the rarity of their conditions. Pediatric orphan drugs are vital in addressing the unique medical needs of children with rare diseases and improving their health outcomes and quality of life.
According to MRAResearch’s new survey, global Pediatric Orphan Drugs market is projected to reach US$ 102180 million in 2033, increasing from US$ 51490 million in 2022, with the CAGR of 10.5% during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Pediatric Orphan Drugs market research.
According to our “ Pharma & Healthcare Research Center” statistics, the global sales of Orphan Drugs reached $139170 million in 2022. The North America region was the world largest Orphan Drugs market, accounting for 40% of Orphan Drugs sales in 2022, followed by Asia-Pacific. The global market for pediatric orphan drugs has been growing steadily in recent years due to increasing awareness of rare pediatric diseases, advancements in medical research and technology, and improved regulatory support for pediatric drug development.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Pediatric Orphan Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Recordati SpA
Novartis
Celgene
Abbvie
Orpharma
Amgen
Amryt Pharma Plc.
Johnson & Johnson
GSK
Bristol-Myers Squibb Company
Roche Holding
Pfizer
Sanofi
Takeda
Segment by Type
Oncology Drugs
Gastrointestinal Drugs
Neurology Drugs
Cardio-vascular Drugs
Others
Hospital Pharmacies
Retail pharmacies
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Pediatric Orphan Drugs report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
According to MRAResearch’s new survey, global Pediatric Orphan Drugs market is projected to reach US$ 102180 million in 2033, increasing from US$ 51490 million in 2022, with the CAGR of 10.5% during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Pediatric Orphan Drugs market research.
According to our “ Pharma & Healthcare Research Center” statistics, the global sales of Orphan Drugs reached $139170 million in 2022. The North America region was the world largest Orphan Drugs market, accounting for 40% of Orphan Drugs sales in 2022, followed by Asia-Pacific. The global market for pediatric orphan drugs has been growing steadily in recent years due to increasing awareness of rare pediatric diseases, advancements in medical research and technology, and improved regulatory support for pediatric drug development.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Pediatric Orphan Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Recordati SpA
Novartis
Celgene
Abbvie
Orpharma
Amgen
Amryt Pharma Plc.
Johnson & Johnson
GSK
Bristol-Myers Squibb Company
Roche Holding
Pfizer
Sanofi
Takeda
Segment by Type
Oncology Drugs
Gastrointestinal Drugs
Neurology Drugs
Cardio-vascular Drugs
Others
Segment by Application
Hospital Pharmacies
Retail pharmacies
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Pediatric Orphan Drugs report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source